Medtronic (MDT) Competitors

In the previous week, Intuitive Surgical had 76 more articles in the media than Medtronic. MarketBeat recorded 105 mentions for Intuitive Surgical and 29 mentions for Medtronic. Medtronic's average media sentiment score of 1.06 beat Intuitive Surgical's score of 0.33 indicating that Medtronic is being referred to more favorably in the news media.

83.6% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 0.3% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Intuitive Surgical currently has a consensus price target of $523.46, suggesting a potential upside of 51.54%. Medtronic has a consensus price target of $98.21, suggesting a potential upside of 18.04%. Given Intuitive Surgical's stronger consensus rating and higher possible upside, equities analysts plainly believe Intuitive Surgical is more favorable than Medtronic.

Medtronic has higher revenue and earnings than Intuitive Surgical. Medtronic is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Intuitive Surgical has a net margin of 28.45% compared to Medtronic's net margin of 13.20%. Intuitive Surgical's return on equity of 17.09% beat Medtronic's return on equity.

Intuitive Surgical has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 2.5%. Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.5%. Abbott Laboratories pays out 70.6% of its earnings in the form of a dividend. Medtronic pays out 77.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories has raised its dividend for 54 consecutive years and Medtronic has raised its dividend for 49 consecutive years.

In the previous week, Abbott Laboratories had 80 more articles in the media than Medtronic. MarketBeat recorded 109 mentions for Abbott Laboratories and 29 mentions for Medtronic. Medtronic's average media sentiment score of 1.06 beat Abbott Laboratories' score of 0.89 indicating that Medtronic is being referred to more favorably in the news media.

Abbott Laboratories has higher revenue and earnings than Medtronic. Medtronic is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Medtronic has a net margin of 13.20% compared to Abbott Laboratories' net margin of 11.65%. Abbott Laboratories' return on equity of 17.65% beat Medtronic's return on equity.

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by insiders. Comparatively, 0.3% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Abbott Laboratories has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Abbott Laboratories currently has a consensus price target of $118.61, indicating a potential upside of 17.77%. Medtronic has a consensus price target of $98.21, indicating a potential upside of 18.04%. Given Medtronic's higher possible upside, analysts plainly believe Medtronic is more favorable than Abbott Laboratories.

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by company insiders. Comparatively, 0.3% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Boston Scientific presently has a consensus target price of $79.84, suggesting a potential upside of 81.65%. Medtronic has a consensus target price of $98.21, suggesting a potential upside of 18.04%. Given Boston Scientific's stronger consensus rating and higher possible upside, research analysts plainly believe Boston Scientific is more favorable than Medtronic.

Medtronic has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

In the previous week, Boston Scientific had 7 more articles in the media than Medtronic. MarketBeat recorded 36 mentions for Boston Scientific and 29 mentions for Medtronic. Medtronic's average media sentiment score of 1.06 beat Boston Scientific's score of 0.79 indicating that Medtronic is being referred to more favorably in the news media.

Boston Scientific has a net margin of 17.29% compared to Medtronic's net margin of 13.20%. Boston Scientific's return on equity of 19.17% beat Medtronic's return on equity.

Boston Scientific has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

In the previous week, Johnson & Johnson had 115 more articles in the media than Medtronic. MarketBeat recorded 144 mentions for Johnson & Johnson and 29 mentions for Medtronic. Medtronic's average media sentiment score of 1.06 beat Johnson & Johnson's score of 0.97 indicating that Medtronic is being referred to more favorably in the news media.

Johnson & Johnson has a net margin of 21.48% compared to Medtronic's net margin of 13.20%. Johnson & Johnson's return on equity of 32.86% beat Medtronic's return on equity.

Johnson & Johnson has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Johnson & Johnson currently has a consensus target price of $265.30, suggesting a potential upside of 4.89%. Medtronic has a consensus target price of $98.21, suggesting a potential upside of 18.04%. Given Medtronic's higher possible upside, analysts plainly believe Medtronic is more favorable than Johnson & Johnson.

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.3% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.1%. Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.5%. Johnson & Johnson pays out 62.1% of its earnings in the form of a dividend. Medtronic pays out 77.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has increased its dividend for 64 consecutive years and Medtronic has increased its dividend for 49 consecutive years.

Johnson & Johnson has higher revenue and earnings than Medtronic. Medtronic is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.